Westover Capital Advisors LLC Takes $648,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Westover Capital Advisors LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 10,483 shares of the company’s stock, valued at approximately $648,000.

A number of other hedge funds have also bought and sold shares of AMPH. Commonwealth Equity Services LLC grew its stake in shares of Amphastar Pharmaceuticals by 37.2% in the third quarter. Commonwealth Equity Services LLC now owns 9,861 shares of the company’s stock worth $454,000 after acquiring an additional 2,674 shares during the period. Stratos Wealth Partners LTD. purchased a new stake in Amphastar Pharmaceuticals in the third quarter worth approximately $215,000. Shariaportfolio Inc. bought a new stake in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $575,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Amphastar Pharmaceuticals by 20.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,436 shares of the company’s stock valued at $434,000 after buying an additional 1,582 shares during the last quarter. Finally, Mackenzie Financial Corp purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $258,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AMPH. JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price target on the stock. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $66.00.

Insider Buying and Selling

In related news, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now directly owns 21,326 shares of the company’s stock, valued at approximately $1,006,160.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 13,500 shares of company stock valued at $634,310. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

AMPH traded up $0.75 during midday trading on Thursday, reaching $42.83. The company had a trading volume of 192,447 shares, compared to its average volume of 445,129. The business has a 50-day moving average of $43.89 and a two-hundred day moving average of $50.82. The company has a market cap of $2.09 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.99 and a beta of 0.85. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 1 year low of $35.93 and a 1 year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The firm had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. As a group, equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.